{"entity":{"id":"nct07849231","kind":"trial","name":"A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms","aka":[],"tldr":"A phase 1 trial of DMR-001 run by Damora Therapeutics, now recruiting.","summary":"A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms is a phase 1 interventional study registered as NCT07849231 by Damora Therapeutics, with 250 participants planned, started 2026-09. Conditions recorded: Myeloproliferative Neoplasms (MPNs). Interventions recorded: DMR-001 and Ruxolitinib.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07849231","url":"https://clinicaltrials.gov/study/NCT07849231"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["dmr-001"],"companies":["damora-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07849231","phase":"1","setting":"A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies, Administered Alone or in Combination With Ruxolitinib, in Participants With CALR-mutant Myeloproliferative Neoplasms","sponsor":"Damora Therapeutics","enrolled":250,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07849231/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"dmr-001","kind":"drug","name":"DMR-001","route":"/drugs/dmr-001/"}],"company":[{"id":"damora-therapeutics","kind":"company","name":"Damora Therapeutics","route":"/companies/damora-therapeutics/"}]}}